Assenagon Asset Management S.A. Has $23.66 Million Stock Holdings in Solventum Corporation $SOLV

Assenagon Asset Management S.A. decreased its position in shares of Solventum Corporation (NYSE:SOLV) by 43.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 362,404 shares of the company’s stock after selling 280,747 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Solventum were worth $23,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the stock. Independent Franchise Partners LLP boosted its stake in Solventum by 27.2% in the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after buying an additional 2,758,174 shares in the last quarter. Norges Bank acquired a new position in Solventum in the fourth quarter valued at approximately $147,467,000. Diamond Hill Capital Management Inc. boosted its position in shares of Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after purchasing an additional 1,272,921 shares in the last quarter. Boston Partners grew its stake in shares of Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the period. Finally, Geode Capital Management LLC increased its position in Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have commented on SOLV. Piper Sandler reduced their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Stifel Nicolaus cut their target price on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. UBS Group cut shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Thursday, May 14th. Finally, KeyCorp upped their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Stock Performance

Solventum stock opened at $79.56 on Friday. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The stock’s 50 day simple moving average is $74.58 and its two-hundred day simple moving average is $74.62. The stock has a market cap of $13.78 billion, a price-to-earnings ratio of 9.75, a PEG ratio of 1.20 and a beta of 0.69.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.